Teva Pharmaceutical Industries Ltd ADR
TEVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$48.00 | Zvz | Kjfckkbl |
Teva Earnings: Robust Gains From Austedo and Ajovy Fuel Sales Growth and Boost Margin
No-moat Teva reported second-quarter earnings that were slightly ahead of our expectations. Total sales were up 2.4% year over year, driven by strong performance from Teva’s key innovative medicines. We are raising our fair value estimate to $11 from $10.50 after baking in impacts from our raised near-term outlook as well as time value of money.